Mugglin, C., Egger, M., & al., E. (2019). Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study. *PLoS ONE, 14*(11), [e0224837]. https://doi.org/10.1371/journal.pone.0224837

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
10.1371/journal.pone.0224837

Link to publication record in Explore Bristol Research
PDF-document

This is the final published version of the article (version of record). It first appeared online via Public Library of Science at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224837. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study

Catrina Mugglin1,*, Andreas D. Haas1, Joep J. van Oosterhout2,3, Malango Msukwa4,5, Lyson Tenthani1,6, Janne Estill1,5, Matthias Egger1, Olivia Keiser1,5

1 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 2 Dignitas International, Zomba, Malawi, 3 Department of Medicine, College of Medicine, University of Malawi, Blantyre, Malawi, 4 Baobab Health Trust, Lilongwe, Malawi, 5 Institute of Global Health, University of Geneva, Geneva, Switzerland, 6 I-TECH Malawi, Lilongwe, Malawi

* catrina.mugglin@ispm.unibe.ch

Abstract

Objectives
We examine long-term retention of adults, adolescents and children on antiretroviral therapy under different HIV treatment guidelines in Malawi.

Design
Prospective cohort study.

Setting and participants
Adults and children starting ART between 2005 and 2015 in 21 health facilities in southern Malawi.

Methods
We used survival analysis to assess retention at clinic level, Cox regression to examine risk factors for loss to follow up, and competing risk analysis to assess long-term outcomes of people on antiretroviral therapy (ART).

Results
We included 132,274 individuals in our analysis, totalling 270,256 person years of follow up (PYFU; median per patient 1.3, interquartile range (IQR) 0.26–3.1), 62% were female and the median age was 32 years. Retention on ART was lower in the first year on ART compared to subsequent years for all guideline periods and age groups. Infants (0–3 years), adolescents and young adults (15–24 years) were at highest risk of LTFU. Comparing the different calendar periods of ART initiation we found that retention improved initially, but remained stable thereafter.
Conclusion

Even though the number of patients and the burden on health care system increased substantially during the study period of rapid ART expansion, retention on ART improved in the early years of ART provision, but gains in retention were not maintained over 5 years on ART. Reducing high attrition in the first year of ART should remain a priority for ART programs, and so should addressing poor retention among adolescents, young adults and men.

Introduction

In 2014 UNAIDS released the “90-90-90” targets and antiretroviral therapy (ART) for prevention of HIV transmission became key to the response to the global HIV epidemic [1]. With the “90-90-90” targets UNAIDS aims to end the HIV epidemic by ensuring that the majority of people infected with HIV are on effective ART and can no longer transmit the virus: by 2020, 90% of all people living with HIV should know their status, 90% of people diagnosed should receive ART, and 90% of the people on ART should achieve viral load suppression.

The latest World Health Organization (WHO) recommendation that all people living with HIV should initiate ART regardless of clinical or immunological stage facilitates early uptake of ART, but long-term retention on ART is crucial for the success of the 90-90-90 strategy, as people who stop treatment experience HIV replication and may acquire ART resistance and transmit the virus [2,3]. Therefore, treatment programs face the challenge to extend ART to all HIV-infected patients, and at the same time retain the expanding number of patients on lifelong ART [4,5]. Studies suggest that people who initiate ART in a less advanced stage of the disease have worse retention than those who are sick when they begin therapy [6–8]. High rates of ART uptake among asymptomatic PLHIV due to universal ART eligibility may thus lead to worse retention [9].

Several systematic reviews have shown that retention on ART is suboptimal and treatment programs need to implement interventions to improve retention to meet UNAIDS targets [10–12]. Retention in care is particularly challenging among adolescents [13,14], pregnant women, and their HIV-exposed children [7,15] and the latest WHO guidelines promote differentiated care models to address the different needs for HIV care services for different patient populations. Intervention to improve retention that are targeted to specific populations including teen friendly services [16] or fewer clinic visits for patients stable on ART [16] are promising interventions. Several studies have shown that loss to follow-up is a substantial problem in Malawi’s ART programme, reported attrition is highest in adolescents [13,14] and women who started ART in the Option B+ programme [7,8]. Most studies have analyzed loss to follow-up in either adults or children and in limited geographical areas.

We examine retention in care by year of starting ART to assess the impact of expanded access to ART on retention. We included patients from a large part of Malawi and from all age groups to identify populations in the greatest need for tailored interventions to improve retention.

Methods

The Malawi ART programme

Malawi introduced free ART in 2004, using a public health approach that standardizes ART regimens and clinically monitors patients for toxicity and treatment failure, in 2011 viral load (VL) monitoring was introduced. Patients are followed monthly for the first 6 months, and
every two or three months thereafter. In 2003, Malawi issued the first national HIV management guidelines. Recommendations for when to start ART, and which ART regimens should be used, have changed over time (S1 Table), generally in line with WHO guidance. National guidelines were first revised in April 2006 (when the CD4 threshold for ART eligibility changed from 200 to 250 cells/μl), and again in April 2008 (CD4 threshold remained at 250 cells/μl), July 2011 (CD4 threshold changed to 350 cells/μl and all pregnant and breastfeeding women became eligible for lifelong ART when Option B+ was introduced; additionally lifelong ART for all children under 2 years was introduced), and in July 2014 (CD4 threshold changed to 500 cells/μl) [17]. In May 2016 new guidelines were published, introducing universal test-and-treat for all persons living with HIV. Between 2005 and 2011, large ART clinics started using an electronic medical record system (EMRS) operated by the Baobab Health Trust (www.baobabhealth.org) [18]. Recorded characteristics in the EMRS system at ART initiation include sex, age, reason for starting ART (WHO clinical stage, CD4 cell count, pregnant or breastfeeding women, age below 5 years). Registration and follow-up data for patients starting ART are routinely collected. To minimize the risk of incorrectly documenting drug dispensation and visits, healthcare workers used barcode scanners and recorded drug dispensation prospectively at the point of care [18], except during occasional outages of the electronic system, when data were collected on paper forms and entered into the system retrospectively. Tracing of patients lost is performed according to policies published by the Ministry of Health of Malawi. Patients who missed an appointment and did not return to the clinic for more than 60 days were traced by expert clients using phone calls or home visits.

**Inclusion criteria**

We used data from 21 facilities with an EMRS in central and southern Malawi, which began initiating patients on ART between 2004 and 2011, depending on the facility. We used data up to database closures, which was between April 2015 and December 2015. We selected these facilities because they were using the Baobab Health Antiretroviral Therapy (BART) EMRS. All treatment-naive children and adults who started ART in this period at any of the included facilities were eligible for inclusion. Patients initiating ART in the 6 months prior to database closure were not included in the analysis since they would not be able to meet the criteria for becoming LTFU (i.e. not returning to the clinic for more than 6 months).

**Definitions and outcomes**

We defined ART initiation as the first recorded dispensation of ART drugs, and baseline as the date of ART initiation. ART refers to the use of a triple-drug combination therapy. We defined time periods based on the introduction of new national HIV guidelines: from 1.1.2004–31.3.2006; 1.4.2006–31.3.2008; 1.4.2008–30.6.2011; 1.7.2011–30.06.2014 and 1.7.2014–01.05.2016. We combined the first two guideline periods because relatively few patients were enrolled and eligibility criteria did not change substantially (S1 Table).

We defined retention on ART as being alive and on ART. Patients were classified as not retained on ART on the date they stopped treatment, they were lost to follow up (LTFU), or died. Patients transferring to another clinic were censored at the date of transfer. Patients were classified as having stopped treatment if they were known to be alive, but were no longer on ART. LTFU was defined as not having returned to the clinic for more than six months [19,20]. Once classified as LTFU, patients remain in this state even if they later returned to care to avoid bias caused by transient interruptions [21]. The date of LTFU was defined as the day of the patient’s last visit to the clinic.

We used the STROBE cohort reporting guidelines. [22] (S3 Table).
Statistical analyses
We used descriptive statistics to examine the characteristics of individuals at the start of ART. We performed survival analyses to describe retention, LTFU, transfer-out, death, and stopping ART. We followed patients from ART initiation until death, transfer out, treatment stop, or censored patients administratively when they stopped being at risk of LTFU (i.e. six months before database closure). First, we plotted crude retention percentages and 95% confidence intervals stratified by age at ART initiation, sex, years on ART, and guideline period. Second, we plotted sub-distribution hazard functions for the cumulative incidence of LTFU, transfer-out, death and stopping ART [23]. We considered death, transfer-out, stopping ART and LTFU as competing events. Third, we used univariable and multivariable Cox proportional hazard models to calculate unadjusted and adjusted hazard ratios (HR) with 95% Confidence Intervals (CI) for factors associated with LTFU. To meet the proportional hazard assumptions, we split follow-up time in three periods (0–1 year, >1–2 years, >2–5 years and >6–8 years on ART) and fitted different Cox models for each period. We adjusted the analyses for age, sex, treatment guideline period at ART initiation and reason for starting ART. We used cluster-based robust standard errors to account for clustering of patients within facilities. Data were analysed with STATA 13.0 (STATA Corporation, College Station, TX).

Ethical approval
The National Health Sciences Research Committee in Malawi and the Cantonal Ethics Committee of Bern in Switzerland granted ethical approval for the study. Individual informed consent was waived since we analyzed routinely collected data only.

Results
Baseline characteristics and study population
Between 2005 and 2015, 132,274 individuals met our inclusion criteria, totalling 270,256 person years of follow up (PYFU; median per patient 1.3, Interquartile range (IQR) 0.26–3.1). We excluded patients with prior ART experience (N = 25,491), those who started ART after analysis closure (N = 4,254) and those with other inconsistencies in data (N = 203). Characteristics of patients excluded from the analysis were similar to those included, except that patients from central hospitals and those who initiated ART in clinical stage III or IV were overrepresented among excluded patients (S2 Table). Median age at ART initiation was 32.5 years (IQR 26.3–39.6); 62% of patients were female. Most patients (77.8%) started ART for their own health, and 16.6% were women starting ART under Option B+. The reason for ART initiation was missing for 5.6% of participants. ART sites included 3 central hospitals, 13 district hospitals, 2 health centres, and 3 faith-based hospitals. The number of sites increased from one site in 2005, to 21 in 2015. The number of included patients per site varied from 688 to 25,809. Median age at ART initiation decreased from 33.8 years in the period 2005–2008, to 31.8 during 2014–2015 (Table 1). The proportion of females who started ART increased from 57.9% to 62.5%, peaking at 65.3% in 2011–2014, after Option B+ was introduced (Table 1). After this point, approximately 25% of patients started ART under Option B+.

Retention on ART
By the end of the study period, 46% (60,582) of patients were retained on ART at the clinic where they initiated treatment, 16% (20,868) had transferred elsewhere, 4.6% (6,040) had died, 33.1% (43,766) were LTFU, and 0.7% (1,018) had stopped ART.
Table 1. Patient characteristics at initiation of antiretroviral therapy (ART), stratified by Malawi national guideline period for ART initiation (2005–2015).

| Guideline Period of initiating ART | 2005–2008 | 2008–2011 | 2011–2014 | 2014–2015 | TOTAL |
|-----------------------------------|-----------|-----------|-----------|-----------|-------|
| Number of patients (%)            | 13,011 (9.8%) | 37,445 (28.3%) | 67,887 (51.3%) | 13,931 (10.5%) | 132,274 (100.0%) |
| Male                              | 5,474 (42.1%) | 15,473 (41.3%) | 23,585 (34.7%) | 5,224 (37.5%) | 49,729 (37.6%) |
| Female                            | 7,537 (57.9%) | 21,972 (58.7%) | 44,329 (65.3%) | 8,707 (62.5%) | 82,545 (62.4%) |
| Age at ART start (years) (%)      |           |           |           |           |       |
| 0–3                               | 333 (2.6%) | 1,394 (3.7%) | 2,420 (3.6%) | 455 (3.3%) | 4,602 (3.5%) |
| 4–6                               | 260 (2.0%) | 633 (1.7%) | 795 (1.2%) | 181 (1.3%) | 1,869 (1.4%) |
| 7–14                              | 656 (5.0%) | 1,378 (3.7%) | 2,057 (3.0%) | 424 (3.0%) | 4,515 (3.4%) |
| 15–24                             | 1,040 (8.0%) | 3,219 (8.6%) | 10,336 (15.2%) | 2,316 (16.6%) | 16,911 (12.8%) |
| 25–34                             | 4,803 (36.9%) | 14,142 (37.8%) | 26,978 (39.7%) | 5,384 (38.6%) | 51,307 (38.8%) |
| 35–44                             | 3,824 (29.4%) | 10,550 (28.2%) | 16,664 (24.5%) | 3,460 (24.8%) | 34,498 (26.1%) |
| 45–54                             | 1,560 (12.0%) | 4,311 (11.5%) | 5,918 (8.7%) | 1,211 (8.7%) | 13,000 (9.8%) |
| 55+                               | 535 (4.1%) | 1,818 (4.9%) | 2,719 (4.0%) | 500 (3.6%) | 5,572 (4.2%) |
| Median (IQR)                      | 33.82 (27.65–41.1) | 33.72 (27.56–40.7) | 31.78 (25.61–38.84) | 31.83 (25.18–38.78) | 32.49 (26.27–39.64) |

Reason for starting ART

| WHO stage III/IV | 10,046 (77.2%) | 22,562 (60.3%) | 26,260 (38.7%) | 3,945 (28.3%) | 62,813 (47.5%) |
| CD4 cell count measurement | 2,737 (21.0%) | 14,043 (37.5%) | 20,868 (30.7%) | 849 (6.1%) | 38,497 (29.1%) |
| Breastfeeding, pregnancy or Option B+ | 0 (0.0%) | 26 (0.1%) | 18,448 (27.2%) | 3,433 (24.6%) | 21,907 (16.6%) |
| Pediatric* | 33 (0.3%) | 313 (0.8%) | 1,017 (1.5%) | 275 (2.0%) | 1,638 (1.2%) |
| Unknown * | 195 (1.5%) | 501 (1.3%) | 1,294 (1.9%) | 5,429 (39.0%) | 7,419 (5.6%) |
| Health care level |           |           |           |           |       |
| Central Hospital | 9,722 (74.7%) | 13,398 (35.8%) | 12,621 (18.6%) | 2,821 (20.2%) | 38,562 (29.2%) |
| District Hospital | 3,289 (25.3%) | 22,962 (61.3%) | 44,179 (65.1%) | 9,225 (66.2%) | 79,655 (60.2%) |
| Health Center | 0 (0.0%) | 232 (0.6%) | 5,954 (8.8%) | 1,241 (8.9%) | 7,427 (5.6%) |
| Mission Hospital | 0 (0.0%) | 853 (2.3%) | 5,133 (7.6%) | 644 (4.6%) | 6,630 (5.0%) |

* Pediatric includes starting due to known HIV infection and pediatric WHO stage. Children can also start due to WHO stage III / V and CD4 cell count measurement

Fig 1 shows crude retention on ART for different age groups and guideline periods in the first (A), second (B) and fifth (C) year on ART. Retention on ART differed between age groups and between guideline periods. In the first year on ART, retention improved from the first to the second guideline period for males and females. For male participants retention improved thereafter, with the highest retention observed in the most recent time period. Whereas for female participants this trend was only visible for the older participants (age groups 45–54 and >55 years), for those aged 15–24 retention decreased with the introduction of Option B+ in 2011. Retention in adolescents was lower than in other age groups, for both males and females. Among those retained on ART for the first year, retention in the second year on ART was similar between guideline periods, and those aged 15–24 had lower retention than other age groups. Retention during the first year of ART was lower than in the second year of ART for all age groups and guideline periods. For those retained on ART by the end of year 2, retention in year 3–5 on ART were lower for men than for women. The drop in retention for those aged 15–24 nearly disappeared for female participants but remained prominent for males (Fig 1).

Risk factors for LTFU

Table 2 shows the risk of LTFU for different patient groups, stratified by duration on ART. There was no difference between males and females in the univariable model for the first and second year on ART. During years 2–5 on ART, females had a lower risk of becoming LTFU.
Fig 1. Crude retention at clinic according to gender and guideline periods. (A) at 1 year (B) at 2 years for those who were retained by the end of year 1 C) at 5 years for those who were retained at the end of year 2 note that the scale of the y axis does not start at 0.

https://doi.org/10.1371/journal.pone.0224837.g001
than males (HR 0.85, 95% CI 0.78–0.93) and this difference persisted during the years 6–8. After adjusting for guideline period, age at ART start and reason for starting ART, females had a lower risk of LTFU in all periods after ART initiation compared to males (aHR 1st year 0.75, 95% CI 0.72–0.78; 2nd year 0.73, 95% CI 0.68–0.79; 2–5 years 0.77, 95% CI 0.70–0.84, 6–8 years 0.62 95% CI 0.55–0.69) (Table 2). The risk of LTFU decreased from the first guideline period to the second for the first year of ART (HR 0.81, 95% CI 0.67–0.98), this difference persisted in the multivariable model (aHR 0.80, 0.66–0.97). There were only small differences in LTFU risk between guideline periods for all years on ART (Table 2). Infants aged 0–2 years and young adults aged 15–24 years had the highest risk of LTFU during the years 1–5 on ART in both the univariable and the multivariable model. During the years 6–8 children aged 6–14 had the

### Table 2. Results from Cox Regression Model, Hazard ratios (HR) and adjusted Hazard ratios (aHR) for loss to follow up (LTFU) are shown stratified by years of retention on antiretroviral therapy (ART).

| Age at ART start (years) | 1st year on ART (N = 132,274), HR (95% CI) | 2nd year on ART (N = 132,274), aHR (95% CI) | 2–5 years on ART (N = 132,274), aHR (95% CI) | 6–8 years on ART (N = 132,274), aHR (95% CI) |
|-------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|---------------------------------------------|
| 0–2                     | 1.44 (1.17–1.77)                            | 1.15 (1.27–1.89)                            | 1.49 (1.26–1.78)                             | 1.48 (1.28–1.70)                             |
| 3–5                     | 0.91 (0.80–1.04)                            | 0.98 (0.86–1.12)                            | 0.75 (0.54–1.04)                             | 0.72 (0.51–1.02)                             |
| 6–14                    | 0.73 (0.66–0.81)                            | 0.78 (0.71–0.85)                            | 0.83 (0.68–1.01)                             | 0.82 (0.65–1.05)                             |
| 15–24                   | 1.51 (1.43–1.58)                            | 1.35 (1.29–1.40)                            | 1.52 (1.41–1.63)                             | 1.51 (1.38–1.66)                             |
| 25–34                   | 1.00 (ref)                                  | 1.00 (ref)                                  | 1.00 (ref)                                  | 1.00 (ref)                                  |
| 35–44                   | 0.74 (0.71–0.77)                            | 0.79 (0.77–0.81)                            | 0.72 (0.64–0.80)                             | 0.70 (0.65–0.76)                             |
| 45–54                   | 0.70 (0.66–0.75)                            | 0.77 (0.74–0.80)                            | 0.64 (0.59–0.70)                             | 0.62 (0.55–0.69)                             |
| >54                     | 0.84 (0.74–0.95)                            | 0.92 (0.85–0.99)                            | 0.77 (0.66–0.91)                             | 0.75 (0.64–0.88)                             |

### Reason for starting ART

- Own health
  - Univariable (N = 132,274), HR (95% CI)
  - 1.00 (ref)
  - 1.00 (ref)

- Option B+
  - 1.90 (1.65–2.19)
  - 1.84 (1.61–2.11)

---

* all models accounted for site heterogeneity using cluster based robust standard errors
* (calendar years 2005–2008)
† (calendar years 2008–2011)
‡ (calendar years 2011–2014)
** (calendar years 2014–2016)

https://doi.org/10.1371/journal.pone.0224837.t002
highest risk of LTFU. Participants initiating ART when they were 35 years or older, had a lower risk of LTFU compared to those aged 25–34 years. In the first year of ART women starting ART due to Option B+ had a higher risk of LTFU compared to those who initiated for their own health (HR 1.90, 95% CI 1.65–2.19; and aHR 1.84, 95% CI 1.61–2.11); after one year these differences disappeared.

**Competing risks analysis**

Overall retention on ART was 70.0% at 12 months after ART initiation, 65.2% after 2 years, and 50.7% after 5 years. Fig 2 shows the competing risks analysis. Most patients who defaulted from care were LTFU in the first year. In the competing risk analysis death was more common among the oldest age group (>55 years of age) and children compared to those aged 25–34, while LTFU was more common among adolescents and young adults.

**Discussion**

We compared retention on ART for a large group of patients over a period of 10 years of ART provision in central and southern Malawi. Even though the number of patients and the burden...
on the health care system increased substantially during the study period of rapid ART expansion, we found that retention on ART improved in the early years of ART, and stabilized thereafter. Retention on ART at the clinic varied between different age groups, and was lowest among infants and young adults aged 15–24. Males were at higher risk of LTFU than females throughout the study period, despite the introduction of Option B+ in 2011, which increased the number of females starting ART. Older PLHIV (>55 years) were more likely to die than younger persons, irrespective of duration on ART.

Strengths of this study are the large sample size, and the ability to compare data over a long time period of HIV treatment and guideline changes during strong program expansion. Our study also has several limitations. All clinics that have an EMRS have large patient populations. One previous study found that LTFU was higher in sites that used EMRS than in sites that did not and our results may therefore not be representative for all HIV clinics in Malawi [8]. We probably underestimated retention on ART, since patients who we recorded as LTFU may be in care elsewhere after silent or undocumented transfer [24,25]. A study in Lilongwe, Malawi found that 40% of patients recorded as LTFU, who were alive and successfully traced were in care elsewhere [26]. Underreporting of mortality is very common in ART programs [27] and some patients LTFU had probably died [28]. In Lilongwe, an analysis of a tracing programme for the years 2006 to 2010 revealed that 30% of patients LTFU had died [29]. Death among those LTFU might be higher in earlier time periods, when many started ART with advance HIV, compared to later periods. We do not know why people were LTFU, but tracing studies found that the most frequent reasons for not returning to care were undocumented transfer, stopping ART, and death [24]. Tracing studies among children are scarce, in a systematic review of outcomes of HIV-positive patients LTFU only 4 of 30 studies included children [30]. They found no difference in mortality, undocumented transfers and interruption of ART between children and adults. Since our study relied on routine, operational data collection by caregivers who were often overburdened, some data may be incorrect. The frequency of data errors is probably low, due to regular supervision visits by teams from the Ministry of Health and its HIV care stakeholders, and because of our additional logical checks after data entry. Our dataset only included variables required for national monitoring, so we could not consider socioeconomic, some anthropometric and other variables that are known to be associated with patients’ ART outcomes [31].

Our results confirm and extend those of earlier studies of retention on ART in Malawi and sub-Saharan Africa. Retention in the first year of ART was similar in a study from Malawi covering the time period between 2004 and 2007 [20]. After 12 months of follow up they found that 69.5% of patients were on ART at the same facility. Another study from northern Malawi, covered a comparable timeframe to ours (from 2005–2012) and found similar retention rates in an area of lower HIV prevalence [32]. Studies from Ethiopia, reporting data from 2005–2011 found comparable retention rates [33,34]. A 2015 systematic review of retention on ART between 2008–2013 found that annual attrition decreased after 24 months, and retention was 65%–70% after 3 years on ART [10]. Some studies in sub-Saharan Africa identified the same baseline characteristics that predicted attrition in our analysis (younger age [32] and male gender[35]). Our finding that retention on ART is particularly low in adolescents was also highlighted by other studies from Sub-Saharan Africa [36–39].

Malawi has successfully scaled up ART and sustained initial retention levels in those starting ART more recently. However, there are differences in retention between different patient populations, and patients who are not retained or have inadequate adherence to treatment are at a high risk of viral rebound and drug resistance [40,41]. Program should consider implementing feasible, evidence-based interventions to promote adherence and retention, including
adherence clubs, adherence counseling, text message reminders by telephone, and treatment supporters [42,43].

In conclusion, in central and southern Malawi, retention on ART did not change much over time, even though the number of patients on ART increased rapidly over time and patients starting ART were increasingly asymptomatic and in good health. Since mortality on ART was higher among older participants, it should be further investigated whether mortality in this group is higher compared to HIV negative people of comparable age. Reducing high attrition in the first year of ART should remain a priority for ART programs, and so should addressing poor retention among adolescents, young adults and men.

Supporting information
S1 Table. Malawi national guidelines 2003–2015.
(DOCX)

S2 Table. Comparison of excluded and included patients.
(DOCX)

S3 Table. STROBE checklist.
(DOCX)

Acknowledgments
We would like to thank all the participants of the study, and the staff who collected the data. The study was funded by the Bill and Melinda Gates Foundation (OPP1090200), and the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. CM was supported by a MD-PhD fellowship from Schweizerische Akademie der Medizinischen Wissenschaften (SAMW). OK was supported by professorship grant from the Swiss National Science Foundation (SNF)(163878) and AH was partly supported by a SNF Early Postdoc.Mobility Fellowship (P2BEP3_178602). These funding organizations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of author’s salaries and research material.

Author Contributions
Conceptualization: Catrina Mugglin, Andreas D. Haas, Janne Estill, Olivia Keiser.

Data curation: Malango Msukwa.

Formal analysis: Catrina Mugglin, Andreas D. Haas.

Funding acquisition: Catrina Mugglin, Olivia Keiser.

Investigation: Catrina Mugglin.

Methodology: Catrina Mugglin, Olivia Keiser.

Project administration: Malango Msukwa.

Supervision: Matthias Egger, Olivia Keiser.

Visualization: Catrina Mugglin.

Writing – original draft: Catrina Mugglin, Andreas D. Haas, Joep J. van Oosterhout, Janne Estill, Olivia Keiser.
Writing – review & editing: Catrina Mugglin, Andreas D. Haas, Joep J. van Oosterhout, Malango Msukwa, Lyson Tenthani, Janne Estill, Matthias Egger, Olivia Keiser.

References

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. In: http://Www.Unaids.Org/Sites/Default/Files/Media_Asset/90-90-90_En_0.Pdf. 2014 p. 40.

2. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. Lippincott Williams & Wilkins AIDS; 2009; 23: 1397–404. https://doi.org/10.1097/QAD.0b013e32832b7dca PMID: 19381076

3. Meresse M, March L, Kouanfack C, Bonono R-C, Boyer S, Laborde-Balen G, et al. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Strattle ANRS 12110/ESTHER trial in Cameroon. HIV Med. 2014; 15: 478–87. https://doi.org/10.1111/hiv.12140 PMID: 24589279

4. Yehia BR, French B, Fleishman JA, Metlay JP, Berry SA, Korthuis PT, et al. Retention in care is more strongly associated with viral suppression in HIV-infected patients with lower versus higher CD4 counts. J Acquir Immune Defic Syndr. 2014; 65: 333–9. https://doi.org/10.1097/QAI.000000000000023 PMID: 24129370

5. Yehia BR, Stephens-Shields AJ, Fleishman JA, Berry SA, Agwu AL, Metlay JP, et al. The HIV Care Continuum: Changes over Time in Retention in Care and Viral Suppression. PLoS One. 2015; 10: e0129376. https://doi.org/10.1371/journal.pone.0129376 PMID: 26086089

6. Grimsrud A, Cornell M, Schomaker M, Fox MP, Orrell C, Prozesky H, et al. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. J Epidemiol Community Health. 2016; 70: 549–55. https://doi.org/10.1136/jech-2015-206629 PMID: 26700300

7. Haas AD, Tenthani L, Msukwa MT, Tal K, Jahn A, Gadabu OJ, et al. Retention in care during the first 3 years of antiretroviral therapy for women in Malawi’s option B+ programme: an observational cohort study. lancet HIV. 2016; 3: e175–82. https://doi.org/10.1016/S2352-3018(16)00008-4 PMID: 27036993

8. Tenthani L, Haas AD, Tweya H, Jahn A, van Oosterhout JJ, Chimbwandira F, et al. Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (“Option B+”) in Malawi. AIDS. 2014; 28: 589–98. https://doi.org/10.1097/QAD.00000000000000143 PMID: 24468999

9. Fox MP. Are we shifting attrition downstream in the HIV cascade? lancet HIV. 2016; 3: e554–e555. https://doi.org/10.1016/S2352-3018(16)30149-7 PMID: 27771232

10. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015; 69: 98–108. https://doi.org/10.1097/QAI.0000000000000553 PMID: 25942461

11. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011; 8: e1001056. https://doi.org/10.1371/journal.pmed.1001056 PMID: 21811403

12. Fox MP, Rosen S. Systematic review of retention of pediatric patients on HIV treatment in low and middle-income countries 2008–2013. AIDS. 2015; 29: 493–502. http://www.ncbi.nlm.nih.gov/pubmed/25665496

13. Lall P, Lim SH, Khairuddin N, Kamarulzaman A. Review: an urgent need for research on factors impacting adherence to and retention in care among HIV-positive youth and adolescents from key populations. J Int AIDS Soc. 2015; 18: 19393. Available: http://www.ncbi.nlm.nih.gov/pubmed/25724503 https://doi.org/10.7448/IAS.18.2.19393 PMID: 25724503

14. MacPherson P, Munthali C, Ferguson J, Armstrong A, Kranzer K, Ferrand RA, et al. Service delivery interventions to improve adolescents’ linkage, retention and adherence to antiretroviral therapy and HIV care. Trop Med Int Health. 2015; 20: 1015–32. https://doi.org/10.1111/tmi.12517 PMID: 25877007

15. Harries AD, van Oosterhout JJ, Tenthani L, Jahn A, Zwahlen M, Msukwa MT, et al. HIV transmission and retention in care among HIV-exposed children enrolled in Malawi’s prevention of mother-to-child transmission programme. J Int AIDS Soc. 2017; 20: 21947. https://doi.org/10.7448/IAS.20.1.21947 PMID: 28884524

16. Grimsrud A, Sharp J, Kalombo C, Bekker L-G, Myer L. Implementation of community-based adherence clubs for stable antiretroviral therapy patients in Cape Town, South Africa. J Int AIDS Soc. 2015; 18: 19984. Available: http://www.ncbi.nlm.nih.gov/pubmed/26022654 https://doi.org/10.7448/IAS.18.1.19984 PMID: 26022654

17. Harries AD, Ford N, Jahn A, Schouten EJ, Libamba E, Chimbwandira F, et al. Act local, think global: how the Malawi experience of scaling up antiretroviral treatment has informed global policy. BMC Public Health. 2016; 16: 938. https://doi.org/10.1186/s12889-016-3620-x PMID: 27600800
18. Douglas GP, Gadabu OJ, Joukes S, Mumba S, McKay M V, Ben-Smith A, et al. Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. PLoS Med. 2010;7. https://doi.org/10.1371/journal.pmed.1000319 PMID: 20711476

19. Grimsrud AT, Cornell M, Egger M, Boule A, Myer L. Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. J Clin Epidemiol. 2013; 66: 1006–13. https://doi.org/10.1016/j.jclinepi.2013.03.013 PMID: 23774112

20. Weigel R, Estill J, Egger M, Harries AD, Makombe S, Tweya H, et al. Mortality and loss to follow-up in the first year of ART: Malawi national ART programme. AIDS. 2012; 26: 365–73. https://doi.org/10.1097/QAD.0b013e32834ed814 PMID: 22095194

21. Johnson LF, Estill J, Keiser O, Cornell M, Moolla H, Schomaker M, et al. Do increasing rates of loss to follow-up in antiretroviral treatment programs imply deteriorating patient retention? Am J Epidemiol. 2014; 180: 1208–12. https://doi.org/10.1093/aje/kwu295 PMID: 25399412

22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Int J Surg. 2014; 12: 1495–9. https://doi.org/10.1016/j.ijsu.2014.07.013 PMID: 25046131

23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association. 1999; 94:496–509. http://dx.doi.org/10.1080/01621459.1999.10474144

24. Zürcher K, Mooser A, Andereg N, Tymejczyk O, Couvillon MJ, Nash D, et al. Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. Trop Med Int Health. 2017; 22: 375–387. https://doi.org/10.1111/tmi.12843 PMID: 28102610

25. Geng EH, Odeny TA, Lyamuya R, Nakiwoga-Muwanga A, Diero L, Bwana M, et al. Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. Clin Infect Dis. 2016; 62: 935–944. https://doi.org/10.1093/cid/ciy304 PMID: 26879625

26. Weigel R, Hochgesang M, Brinkhof MW, Hosseinipour MC, Boxshall M, Mhango E, et al. Outcomes and associated risk factors of patients traced after being lost to follow-up from antiretroviral treatment in Lilongwe, Malawi. BMC Infect Dis. 2011; 11: 31. https://doi.org/10.1186/1471-2334-11-31 PMID: 21272350

27. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One. 2009; 4: e5790. https://doi.org/10.1371/journal.pone.0005790 PMID: 19495419

28. Haas AD, Zaniekiewski E, Anderegg N, Ford N, Fox MP, Vinikoor M, et al. Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc. 2018;21. https://doi.org/10.1002/jia2.25084 PMID: 29479867

29. Tweya H, Feldacker C, Estill J, Jahn A, Ng’ambi W, Ben-Smith A, et al. Are they really lost? “true” status and reasons for treatment discontinuation among HIV infected patients on antiretroviral therapy considered lost to follow up in Urban Malawi. PLoS One. 2013; 8: e75761. https://doi.org/10.1371/journal.pone.0075761 PMID: 24086627

30. Zürcher K, Mooser A, Andereg N, Tymejczyk O, Couvillon MJ, Nash D, et al. Outcomes of HIV-positive patients lost to follow-up in African treatment programmes. Trop Med Int Health. 2017; 22: 375–387. https://doi.org/10.1111/tmi.12843 PMID: 28102610

31. Gwynn RC, Fawzy A, Viho I, Wu Y, Abrams EJ, Nash D. Risk factors for loss to follow-up prior to ART initiation among patients enrolling in HIV care with CD4+ cell count ≥200 cells/μL in the multi-country MTCT-Plus Initiative. BMC Health Serv Res. 2015; 15: 247. https://doi.org/10.1186/s12913-015-0898-9 PMID: 26108273

32. Koole O, Houben RM, Mzembe T, Van Boeckel TP, Kayange M, Jahn A, et al. Improved retention of patients starting antiretroviral treatment in Karonga District, northern Malawi, 2005–2012. J Acquir Immune Defic Syndr. 2014; 67: e27–e33. https://doi.org/10.1097/QAI.0000000000000252 PMID: 24977375

33. Tiruneh YM, Galárraga O, Genberg B, Wilson IB. Retention in Care among HIV-Infected Adults in Ethiopia, 2005–2011: A Mixed-Methods Study. PLoS One. 2016; 11: e0156619. https://doi.org/10.1371/journal.pone.0156619 PMID: 27272890

34. Bucciardini R, Fragola V, Abegaz T, Lucattini S, Halifom A, Tadesse E, et al. Retention in Care of Adult HIV Patients Initiating Antiretroviral Therapy in Tigray, Ethiopia: A Prospective Observational Cohort Study. PLoS One. 2015; 10: e0136117. https://doi.org/10.1371/journal.pone.0136117 PMID: 26340271
35. Koole O, Tsui S, Wabwire-Mangen F, Kwesigabo G, Menten J, Mulenga M, et al. Retention and risk factors for attrition among adults in antiretroviral treatment programmes in Tanzania, Uganda and Zambia. Trop Med Int Health. 2014; 19: 1397–410. https://doi.org/10.1111/tmi.12386 PMID: 25227621

36. Okoboi S, Ssali L, Yansaneh AI, Bakanda C, Birungi J, Nantume S, et al. Factors associated with long-term antiretroviral therapy attrition among adolescents in rural Uganda: a retrospective study. J Int AIDS Soc. 2016; 19: 20841. Available: http://www.ncbi.nlm.nih.gov/pubmed/27443271 https://doi.org/10.7448/IAS.19.5.20841 PMID: 27443271

37. Adejumo OA, Malee KM, Ryscavage P, Hunter SJ, Taiwo BO. Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review. J Int AIDS Soc. 2015; 18: 20049. Available: http://www.ncbi.nlm.nih.gov/pubmed/26385853 https://doi.org/10.7448/IAS.18.1.20049 PMID: 26385853

38. Matyanga CMJ, Takarinda KC, Owiti P, Mutasa-Apollo T, Mugurungi O, Buruwe L, et al. Outcomes of antiretroviral therapy among younger versus older adolescents and adults in an urban clinic, Zimbabwe. Public Heal action. 2016; 6: 97–104. https://doi.org/10.5588/pha.15.0077 PMID: 27358802

39. Kranzer K, Bradley J, Musaazi J, Nyathi M, Gunguwo H, Ndebele W, et al. Loss to follow-up among children and adolescents growing up with HIV infection: age really matters. J Int AIDS Soc. 2017; 20: 21737. https://doi.org/10.7448/IAS.20.1.21737 PMID: 28715158

40. Harrigan PR, Hogg RS, Dong WWY, Yip B, Wynhoven B, Woodward J, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005; 191: 339–47. https://doi.org/10.1086/427192 PMID: 15633092

41. Nachega JB, Hislop M, Dowdy DW, Chaisson L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007; 146: 564–73. Available: http://www.ncbi.nlm.nih.gov/pubmed/17438315 https://doi.org/10.7326/0003-4819-146-6-200704170-00007 PMID: 17438315

42. Mills EJ, Lester R, Thorlund K, Lorenzi M, Muldoon K, Kanters S, et al. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. Lancet HIV. Elsevier Ltd; 2014; 1: e104–11. https://doi.org/10.1016/S2352-3018(14)00003-4 PMID: 26424119

43. Nachega JB, Skinner D, Jennings L, Magidson JF, Altice FL, Burke JG, et al. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. Patient Prefer Adherence. 2016; 10: 683–90. https://doi.org/10.2147/PPA.S100002 PMID: 27175068